An interventional study of Gonadotropin Releasing Hormone Agonists (GNRH-A) and Human chorionic gonadotropin in Ovulation Induction, In Vitro Fertilization (IVF) and Infertility, Female, sponsored by Ginegorama S.L.. Status unknown at 1 site in Spain. Open to female participants aged 18 Years to 48 Years. Per ClinicalTrials.gov, last updated 2017-12-11.
Sponsored by Ginegorama S.L. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Infertility, Female with a site in Spain — 8 open to participants now, 8 under way, none of them phase 3. Infertility, Female · Spain.
Among the 33 studies in Infertility, Female with a site in Spain, this one is the 5th largest by planned enrollment of the 26 interventional ones that give a count, is one of 5 that started in 2017, is one of 16 with no phase, and was the 10th registered.
552 studies on the registry are indexed under Infertility, Female; 135 are open to participants now.
Browse Infertility, Female studies →8 of the 33 studies in Infertility, Female with a site in Spain are open now. Recruiting first, the newest first:
Instituto Valenciano de Infertilidad, IVI VALENCIA · Sites in Spain
Ages 18–35 · Women only
Instituto Valenciano de Infertilidad, IVI VALENCIA · Sites in Spain
Women only
Instituto Valenciano de Infertilidad, IVI VALENCIA · Sites in Spain
Ages 18–35 · Women only
Instituto Valenciano de Infertilidad, IVI VALENCIA · Sites in Spain
Ages 18–35 · Women only
Instituto Valenciano de Infertilidad, IVI VALENCIA · Sites in Spain
Ages 18–50 · Women only · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 90 Infertility, Female studies recruiting now, 11 (12%) set no upper age limit and 79 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 48 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 100 across 378 interventional studies indexed under Infertility, Female.
Median enrollment 94 across the 26 interventional studies, 342 across the 7 observational. Of the 22 that completed or were terminated, 2 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 33 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Ginegorama S.L. as lead sponsor.
Ginegorama S.L. has 1 study filed under Infertility, Female — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 33 studies in Infertility, Female with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Agonist triggering in controlled ovarian stimulation protocols is being used during last years (among high responder patients to avoid OHSS).
Indeed, agonist triggering is more physiologic than HCG triggering. Investigators propose to compare the effectiveness of both types of trigger among three different subsets of patients:
During the last years, ovulation triggering in controlled ovarian stimulation protocols has been used specially to avoid hyperstimulation syndromes (OHSS). Indeed, the substitution of the classical HCG triggering by the agonist one, reduces almost to zero the risk of OHSS.
On the other hand poor responder patients to ovarian stimulation represent a challenge in assisted reproduction. Defining poor responders is not easy, but we can define them as those patients with less than 4 eggs obtained after oocyte retrieval.
Different strategies have been proposed to overcome this problem. In other words, to obtain more oocytes. These include an increase in FSH doses, an increase in FSH action by adding sensitizers agents.
Among the possible strategies, investigators propose the agonist triggering. HCG (classical) triggering represents the use of a LH-like product (with a prolonged action). The administration of a GnRH agonist provoke the production and liberation of both FSH and LH. Thus, the pro-ovulatory action is more physiologic , and possibly, more effective.
So, the use of a triggering protocol that nowadays is being used among high responders (thus reducing the OHSS risk) is proposed for both poor responder and normo-responder patients trying to achieve more oocytes, and specifically more mature oocytes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval. Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment.
Drug: Human chorionic gonadotropin
Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval) Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment.
Drug: Gonadotropin Releasing Hormone Agonists (GNRH-A)
Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval. Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment.
Drug: Human chorionic gonadotropin
Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval) Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment.
Drug: Gonadotropin Releasing Hormone Agonists (GNRH-A)
Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval. Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment.
Drug: Human chorionic gonadotropin
Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval) Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment.
Drug: Gonadotropin Releasing Hormone Agonists (GNRH-A)
Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.
Also known as: Agonist trigger
Administration of Human chorionic gonadotropin (HCG) 250 IU subcutaneously , 36 hours before ovum pick-up in IVF treatments.
Also known as: HCG trigger
Mature oocytes
Number of mature oocytes achieved after oocyte retrieval.
Time frame: Up to 24 weeks
Relation mature oocytes/punctured oocytes
Relation between the number of mature oocytes and the follicles.
Time frame: Up to 24 weeks
Fertilized oocytes
Number of fertilized oocytes
Time frame: Up to 24 weeks
Relation fertilized oocytes/achieved Mature oocytes
Relation between the number of fertilized oocytes and the mature oocytes achieved.
Time frame: Up to 24 weeks
Number of blastocysts developed
Number of blastocysts developed in each arm of the study.
Time frame: Up to 24 weeks
Cancelled cycles
Percentage of cancelled cycles
Time frame: Up to 24 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2017; primary completion for Feb 2018, 2 months later.
Of 142 non-industry interventional studies with no phase under Infertility, Female, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 2 months is below that.
Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.